Table 2.
Characteristics of RA cohort
| Disease duration (month), median (IQR) | 48 (16.5–120) |
| RF or anti-CCP positive, n(%) | 119 (64.32%) |
| ESR (mm/H), mean + SE | 33.20 ± 2.30 |
| CRP (mg/L), mean + SE | 19.48 ± 2.44 |
| Tender Joint Count, mean + SE | 6.55 ± 0.46 |
| Swollen joint count, mean + SE | 3.66 ± 0.33 |
| DAS28, mean + SE | 4.06 ± 0.11 |
| SDAI, mean + SE | 21.04 ± 1.21 |
| CDAI, mean + SE | 19.48 ± 1.04 |
| HAQ, median (IQR) | 5 (1–13) |
| Treatment—NSAIDs in use, n(%) | 77 (41.62%) |
| Glucocorticoids in use, n(%) | 56 (30.27%) |
| DMARDs in use, n(%) | 116 (62.70%) |
| -- MTX in use, n(%) | 61 (52.59%) |
| LEF in use, n(%) | 53 (45.69%) |
| HCQ in use, n(%) | 56 (48.28%) |
Data are median, mean ± SE or N(%)
RA rheumatoid arthritis, RF rheumatoid factor, anti-CCP anti-cyclic citrullinated peptide antibody, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS28 disease activity score 28 joint count, SDAI simplified disease activity index scoring, CDAI clinical disease activity index scoring, HAQ health assessment questionnaire scoring, NSAIDs non-steroidal anti-inflammatory drugs, DMARDs disease modifying anti-rheumatic drugs, MTX methotrexate, LEF leflunomide, HCQ hydroxychloroquine